Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Wedbush lowered their Q2 2025 earnings per share estimates for Oruka Therapeutics in a research report issued on Wednesday, May 14th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.46) per share for the quarter, down from their previous estimate of ($0.43). Wedbush has a "Outperform" rating and a $40.00 price objective on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.41) per share. Wedbush also issued estimates for Oruka Therapeutics' Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.82) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.05) EPS, FY2027 earnings at ($2.52) EPS and FY2028 earnings at ($3.34) EPS.
A number of other equities analysts have also weighed in on ORKA. Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday. Wolfe Research began coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 target price for the company. BTIG Research began coverage on shares of Oruka Therapeutics in a report on Thursday. They issued a "buy" rating for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Oruka Therapeutics has an average rating of "Buy" and an average target price of $40.38.
Check Out Our Latest Research Report on ORKA
Oruka Therapeutics Price Performance
Shares of NASDAQ:ORKA traded down $0.24 during mid-day trading on Monday, reaching $10.95. 135,502 shares of the company traded hands, compared to its average volume of 225,915. The company's 50 day moving average price is $9.79 and its 200-day moving average price is $14.29. The firm has a market cap of $409.98 million, a PE ratio of -1.75 and a beta of 0.25. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $31.13.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.17.
Hedge Funds Weigh In On Oruka Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC boosted its holdings in shares of Oruka Therapeutics by 17.7% during the 4th quarter. FMR LLC now owns 5,512,300 shares of the company's stock valued at $106,883,000 after purchasing an additional 830,000 shares during the last quarter. Fairmount Funds Management LLC boosted its holdings in shares of Oruka Therapeutics by 5.0% during the 4th quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock valued at $65,382,000 after purchasing an additional 160,000 shares during the last quarter. VR Adviser LLC boosted its holdings in shares of Oruka Therapeutics by 6.5% during the 4th quarter. VR Adviser LLC now owns 3,285,620 shares of the company's stock valued at $63,708,000 after purchasing an additional 200,000 shares during the last quarter. RTW Investments LP boosted its stake in Oruka Therapeutics by 5.1% during the fourth quarter. RTW Investments LP now owns 1,945,649 shares of the company's stock valued at $37,726,000 after buying an additional 95,001 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Oruka Therapeutics by 4,161.2% during the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after buying an additional 1,572,853 shares during the last quarter. Institutional investors own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Read More
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
